|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 920 Massachusetts Avenue, NW |
Address2 | Suite 500 |
City | WASHINGTON |
State | DC |
Zip Code | 20001 |
Country | USA |
3. Principal place of business (if different than line 2)
City | Plainsboro |
State | NJ |
Zip Code | 08536 |
Country | USA |
|
5. Senate ID# 284790-12
|
||||||||
|
6. House ID# 369030000
|
TYPE OF REPORT | 8. Year | 2016 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Brian Branton |
Date | 7/18/2016 11:50:04 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
P.L. 113-54 Drug Quality and Security Act (track and trace supply chain provisions); issues regarding biosimilars; issues regarding 340B; H.R.6 21st Century Cures Act; FDA in HR 3049 FY16 Agriculture Appropriations
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA), Health Resources & Services Administration (HRSA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brian |
Branton |
|
|
|
Lauren |
Semeniuk |
|
|
|
Sarah |
Nordstrom |
|
|
|
Tricia |
Brooks |
|
|
|
Amanda |
Makki |
|
US Senator Lisa Murkowski (R-AK) |
|
Amy |
Wotring |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
National Diabetes Prevention Program; Better care and treatment of people with diabetes under P.L. 111-148 Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 111-152 The Health Care & Education Affordability Reconciliation Act of 2010: Issues related to diabetes generally, and specifically diabetes screening, medical education and death certificate reporting (Catalyst for Better Diabetes), AHRQ and USPSTF diabetes screening standards; diabetes issues in Healthy People 2020 and the Office of Disease Prevention and Health Promotion (ODPHP); H.R. 1192 and S. 586 National Diabetes Clinical Care Commission Act of 2015; P.L. 114-10, Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) for Special Diabetes Program, CHIP, and childhood obesity; S. 84 and H.R. 3658 Gestational Diabetes Act of 2015; H.R. 1190 and S. 141 Protecting Seniors' Access to Medicare Act of 2015 (IPAB repeal); H.R. 2651 Eliminating Disparities in Diabetes Prevention, Access, and Care Act of 2015 (EDDPAC); cost of diabetes generally; S. 320 and H.R. 744 Medical Innovation Act of 2015; S. 2023 and H.R. 3513 Prescription Drug Affordability Act of 2015; H.R. 3742, Access to Marketplace Insurance Act and general allowance for certain third party payments of cost sharing; Congressional recognition of World Hemophilia Day
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Centers For Disease Control & Prevention (CDC), Executive Office of the President (EOP), Natl Institutes of Health (NIH), Labor - Dept of (DOL), Health Resources & Services Administration (HRSA), Indian Health Service, Treasury - Dept of
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brian |
Branton |
|
|
|
Lauren |
Semeniuk |
|
|
|
Sarah |
Nordstrom |
|
|
|
Tricia |
Brooks |
|
|
|
Amanda |
Makki |
|
US Senator Lisa Murkowski (R-AK) |
|
Amy |
Wotring |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Issues related to National Diabetes Prevention Program in FY17 Labor/HHS/Education Appropriations, P.L. 114-113 FY16 Consolidated Appropriations, and P.L. 113-235 FY15 Consolidated and Continuing Appropriations; Issues related to Medicare Part D, FDA, patents, and federal procurement in S.Con.Res.11 FY16 Senate Budget Resolution and H.Con.Res.27 House Budget Resolution; H.R. 3660 and S.3126 Preventive Health Savings Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Lauren |
Semeniuk |
|
|
|
Brian |
Branton |
|
|
|
Sarah |
Nordstrom |
|
|
|
Tricia |
Brooks |
|
|
|
Amanda |
Makki |
|
US Senator Lisa Murkowski (R-AK) |
|
Amy |
Wotring |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Issues related to Medicare Part D, Special Diabetes Program, CHIP, and childhood obesity in P.L. 114-10 Medicare Access and CHIP Reauthorization Act of 2015 (MACRA); H.R. 2102 and S.1131 Medicare Diabetes Prevention Act; H.R. 2404 and S. 1509 Treat and Reduce Obesity Act; Issues related to medical nutrition therapy services to such beneficiaries with pre-diabetes or with risk factors for developing type 2 diabetes H.R. 1686 Medical Nutrition Therapy 2015; issues related to patient diabetes education in H.R. 1726 Access to Quality Diabetes Education Act of 2015; Continuous Glucose Monitoring (CGM); Medicare diabetes screening generally; H.R. 1021 Protecting the Integrity of Medicare Act (PIMA) of 2015; H.R.2005 and S. 1083 Medicare Drug Savings Act of 2015; Physician Quality and Reporting System (PQRS); CMMI Part B Demonstration
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Lauren |
Semeniuk |
|
|
|
Brian |
Branton |
|
|
|
Sarah |
Nordstrom |
|
|
|
Tricia |
Brooks |
|
|
|
Amanda |
Makki |
|
US Senator Lisa Murkowski (R-AK) |
|
Amy |
Wotring |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Protecting Americans from Tax Hikes Act of 2015(PATH) provision of P.L. 114-113 FY16 Consolidated Appropriations; H.R. 880 R&D tax credit; corporate tax inversion generally and in amendments to S.Con.Res.11 FY16 Senate Budget Resolution and S. 1376 FY16 National Defense Authorization Act; interest deductibility IRC 163(j); Treasury proposed debt and equity regulations (Sec. 385)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Lauren |
Semeniuk |
|
|
|
Brian |
Branton |
|
|
|
Sarah |
Nordstrom |
|
|
|
Tricia |
Brooks |
|
|
|
Amanda |
Makki |
|
US Senator Lisa Murkowski (R-AK) |
|
Amy |
Wotring |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
P.L. 114-26 Bipartisan Congressional Trade Priorities and Accountability Act of 2015; EU/US Transatlantic Trade and Investment Partnership (TTIP) (intellectual property, regulatory harmonization)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brian |
Branton |
|
|
|
Lauren |
Semeniuk |
|
|
|
Sarah |
Nordstrom |
|
|
|
Tricia |
Brooks |
|
|
|
Amanda |
Makki |
|
US Senator Lisa Murkowski (R-AK) |
|
Amy |
Wotring |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
H.R. 9 Innovation Act and and S. 1137 PATENT Act (patent litigation and assertion); S.1890 and H.R.3326 Defend Trade Secrets Act of 2015
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brian |
Branton |
|
|
|
Lauren |
Semeniuk |
|
|
|
Sarah |
Nordstrom |
|
|
|
Tricia |
Brooks |
|
|
|
Amanda |
Makki |
|
US Senator Lisa Murkowski (R-AK) |
|
Amy |
Wotring |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code DEF
16. Specific lobbying issues
Issues related to TRICARE pharmacy benefit in HR4909 and S 2943 FY17 National Defense Authorization Act.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Lauren |
Semeniuk |
|
|
|
Brian |
Branton |
|
|
|
Tricia |
Brooks |
|
|
|
Sarah |
Nordstrom |
|
|
|
Amanda |
Makki |
|
US Senator Lisa Murkowski (R-AK) |
|
Amy |
Wotring |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |